Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zealand Pharma's 'More Commercial' CEO Jensen On Lixisenatide And Beyond

This article was originally published in Scrip

Executive Summary

Danish company Zealand Pharma, most noteworthy for developing the thus far commercially disappointing Sanofi-partnered GLP-1 receptor agonist Lyxumia (lixisenatide), appointed its new CEO a year ago, claiming it needed someone with a more commercial focus. Scrip caught up with Britt Meelby Jensen to find out what lessons the company has learned from the Lyxumia episode and how Zealand Pharma is moving beyond diabetes.


Related Content

Finance Watch Public Company Edition: Akcea, Kala Launch IPOs While FOPOs Keep Busy Pace





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts